Anti-MEK1 (phospho T292) antibody (ab5612)
Key features and details
- Rabbit polyclonal to MEK1 (phospho T292)
- Suitable for: WB
- Reacts with: Recombinant fragment
- Isotype: IgG
Overview
-
Product name
Anti-MEK1 (phospho T292) antibody
See all MEK1 primary antibodies -
Description
Rabbit polyclonal to MEK1 (phospho T292) -
Host species
Rabbit -
Tested Applications & Species
Application Species WB Recombinant fragment -
Immunogen
The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of human MEK 1 that contains threonine 292.
-
Positive control
- NIH3T3 cells +/- PDGF.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.30
Preservative: 0.05% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated MEK 1. The final product is generated by affinity chromatography using a MEK 1 derived peptide that is phosphorylated at threonine 292. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab5612 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
WB |
Recombinant fragment
|
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Predicted molecular weight: 50 kDa.
|
Notes |
---|
WB
1/1000. Predicted molecular weight: 50 kDa. |
Target
-
Function
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases. -
Tissue specificity
Widely expressed, with extremely low levels in brain. -
Involvement in disease
Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant. -
Sequence similarities
Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway. - Information by UniProt
-
Alternative names
- Dual specificity mitogen activated protein kinase kinase 1 antibody
- Dual specificity mitogen-activated protein kinase kinase 1 antibody
- ERK activator kinase 1 antibody
see all
Images
-
Peptide Competition and Mutant Analysis: Recombinant wild-type (lanes 1 4) and mutant (T292A) MEK1 (lane 5) treated with ERK to induce phosphorylation was added to background extracts and resolved by SDS PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4oC, then were incubated with 0.50
µ g/mL ab5612 antibody for two hours at room temperature, following prior incubation with: no peptide (1, 5), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphothreonine containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’ 2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5612 blocks the antibody signal, and the T292A mutant is not reactive, demonstrating the specificity of the antibody. The recombinant wild-type and mutant MEK1 were kindly provided by Dr. Natalie Ahn, University of Colorado.
Peptide Competition and Mutant Analysis: Recombinant wild-type (lanes 1 4) and mutant (T292A) MEK1 (lane 5) treated with ERK to induce phosphorylation was added to background extracts and resolved by SDS PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4oC, then were incubated with 0.50 µg/mL ab5612 antibody for two hours at room temperature, following prior incubation with: no peptide (1, 5), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphothreonine containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’ 2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5612 blocks the antibody signal, and the T292A mutant is not reactive, demonstrating the specificity of the antibody. The recombinant wild-type and mutant MEK1 were kindly provided by Dr. Natalie Ahn, University of Colorado.
Protocols
Datasheets and documents
References (0)
ab5612 has not yet been referenced specifically in any publications.